OptumRx Zepbound Coverage: The UnitedHealth Group PBM Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · As of May 2026, confirm directly with your plan

Key Takeaways

• OptumRx is the in-house PBM of UnitedHealth Group, administering pharmacy benefits for UnitedHealthcare plus external payers
• Zepbound coverage depends on the specific plan template and employer benefit design
• The December 2024 FDA approval of tirzepatide for moderate-to-severe OSA created a new coverage pathway
• Self-funded ERISA plans can exclude anti-obesity medications regardless of OptumRx's standard template
• LillyDirect's vial self-pay program offers a workaround for uncovered patients at approximately $349 to $499 monthly

Direct answer

OptumRx coverage of Zepbound depends on the specific plan or employer contract using OptumRx as the pharmacy benefit manager. Many UnitedHealthcare commercial plans cover Zepbound with prior authorization. Self-funded employer plans can exclude anti-obesity medications. The December 2024 FDA approval for moderate-to-severe OSA created a new coverage pathway. Verify directly with your specific plan formulary.

Table of contents

1. OptumRx's role in pharmacy benefits
2. UnitedHealthcare commercial Zepbound coverage
3. UnitedHealthcare Medicare Advantage
4. OptumRx PA criteria for Zepbound
5. The December 2024 OSA pathway
6. Mounjaro coverage for diabetic patients
7. Cost scenarios
8. LillyDirect and the vial self-pay option
9. Self-funded ERISA exclusions
10. Appealing a denial
11. Decision framework
12. FAQ
13. Sources

OptumRx's role in pharmacy benefits

OptumRx is the pharmacy benefit manager arm of Optum, which is a subsidiary of UnitedHealth Group, Inc. UnitedHealth Group is the largest health insurance company in the United States by revenue and membership. OptumRx serves:

• UnitedHealthcare commercial group plans
• UnitedHealthcare Medicare Advantage and Part D plans
• UnitedHealthcare Medicaid managed care plans
• Tricare in some capacities
• State employee health plans
• Large self-funded employers directly
• External commercial insurers contracting with OptumRx

The PBM negotiates pricing, creates formulary templates, processes prior authorizations, operates specialty pharmacies (including BriovaRx, OptumRx Specialty Pharmacy), and provides clinical management programs.

UnitedHealthcare commercial Zepbound coverage

Most UnitedHealthcare commercial plans cover Zepbound with prior authorization, when the underlying employer plan does not exclude anti-obesity medications. The fully insured commercial book of business generally has consistent coverage rules across states, though state mandates produce some variation.

Standard UnitedHealthcare commercial Zepbound coverage includes:

• Tier 3 or specialty tier formulary placement
• Prior authorization required
• BMI 30+ or BMI 27+ with comorbidities
• Structured weight-management program documentation
• Step therapy in some plans

Self-funded employer plans administered by UnitedHealthcare/OptumRx vary widely. Some employer plans extend coverage; others exclude anti-obesity drugs entirely. Reading your specific SPD is essential.

UnitedHealthcare Medicare Advantage

UnitedHealthcare is one of the largest Medicare Advantage providers in the United States. Medicare Part D rules historically exclude weight-loss medications. The 2024 FDA approvals of Wegovy (for cardiovascular risk reduction) and Zepbound (for moderate-to-severe OSA) created alternative pathways that some Medicare Advantage plans now use.

UnitedHealthcare Medicare Advantage Zepbound coverage as of May 2026:

• Standard obesity indication: generally excluded under Medicare Part D weight-loss drug rules
• OSA indication (after December 2024): coverage path with sleep-medicine documentation
• 2025 IRA $2,000 annual out-of-pocket cap applies to covered Part D drugs

Members seeking Zepbound coverage through UnitedHealthcare Medicare Advantage should pursue the OSA indication when applicable, as obesity-only requests typically face exclusion.

OptumRx PA criteria for Zepbound

Standard OptumRx PA for Zepbound (obesity indication) typically requires:

1. BMI 30 or higher, or BMI 27 with documented comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA)
2. Participation in a structured weight-management program, typically 3 to 6 months of documented engagement
3. Absence of contraindications (personal or family history of MTC, MEN 2)
4. Attestation of medical necessity by the prescribing physician
5. For step-therapy plans, prior trial of preferred GLP-1 alternative

Initial approval is generally 6 months, with reauthorization requiring documented weight loss of 5% or more from baseline.

For the OSA indication, separate criteria apply:

• Polysomnography documenting moderate-to-severe OSA (typically AHI 15+)
• BMI 30 or higher
• CPAP intolerance, insufficiency, or contraindication documentation
• Sleep medicine physician co-signature in some plans

The December 2024 OSA pathway

The FDA's December 2024 approval of tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials (Malhotra et al., New England Journal of Medicine 2024), created a new coverage pathway.

For OptumRx-administered plans, the OSA indication is reimbursable as sleep medicine, not as obesity treatment. Plans that exclude anti-obesity drugs can still cover Zepbound under the OSA indication.

The SURMOUNT-OSA trial demonstrated:

• Mean AHI reduction of approximately 25 to 30 events per hour at 15 mg tirzepatide
• Significant percentage of patients moving from severe to mild OSA classification
• Effects observed in both CPAP-using and non-CPAP-using populations
• Concurrent weight loss consistent with SURMOUNT-1 outcomes

Coverage under the OSA pathway has expanded steadily through 2025 and into 2026 across OptumRx-administered plans.

Mounjaro coverage for diabetic patients

Tirzepatide is marketed as Mounjaro for type 2 diabetes and as Zepbound for obesity and OSA. The molecule is identical; the brand name and FDA-approved indication differ.

For UnitedHealthcare members with type 2 diabetes, Mounjaro coverage is substantially more accessible than Zepbound coverage. Most OptumRx formularies include Mounjaro at tier 3 with PA for diabetes management.

Members with both T2DM and obesity may be appropriately prescribed Mounjaro under the diabetes indication. The medication produces similar effects to Zepbound; the difference is which brand name and indication appear on the prescription.

This is not a workaround for non-diabetic patients. Prescribing Mounjaro off-label to non-diabetic patients triggers PA denial when the lack of T2DM diagnosis is visible to the PBM.

Cost scenarios

Scenario	Approximate monthly cost
Covered, tier 3 commercial	$50 to $100
Covered, specialty tier	$100 to $200
With Lilly copay card	$25 to $50 (eligibility-limited)
Uncovered retail cash	Approximately $1,000
LillyDirect 2.5 mg vial	Approximately $349
LillyDirect 5 mg vial	Approximately $499
Medicare Advantage covered (OSA)	Variable, $2,000 annual cap applies

LillyDirect and the vial self-pay option

Eli Lilly's LillyDirect program offers direct patient access to Zepbound through vials at substantially reduced pricing compared to pre-filled pens at retail. The program was launched in early 2024 and expanded through 2025.

Vial pricing as of May 2026:

• 2.5 mg vial: approximately $349 per monthly supply
• 5 mg vial: approximately $499 per monthly supply
• Higher doses: more limited vial availability

The vial program requires the patient to draw doses from vials rather than use pre-filled pens. Lilly provides vial preparation instructions and syringes. Fulfillment is through contracted pharmacies, not through traditional retail pharmacy networks.

For OptumRx members denied coverage, LillyDirect provides a meaningful price reduction from cash retail pricing. Physicians can write prescriptions specifically for LillyDirect fulfillment.

Self-funded ERISA exclusions

ERISA self-funded employer plans administered by UnitedHealthcare/OptumRx can exclude anti-obesity medications as a category. If your SPD excludes the category, prior authorization will not produce coverage.

Options for members in excluded plans:

• Pursue the OSA indication if applicable
• Advocate with HR for benefit expansion
• Use LillyDirect or out-of-pocket options
• Consider compounded tirzepatide as a separate category (different regulatory status, different product)

Some employers have added obesity drug coverage in 2024-2025 in response to employee advocacy and broader cultural shifts. HR conversations have produced real coverage changes in some workplaces.

Appealing a denial

Appeal pathways depend on plan type:

Fully insured commercial: Internal OptumRx appeal, peer-to-peer review, state IRO external review.

ERISA self-funded: Internal appeals per plan procedures, federal court review.

Medicare Advantage Part D: CMS five-level appeals process (redetermination, IRE, ALJ, MAC, federal court).

Medicaid managed care: State Medicaid fair hearing process, varies by state.

Appeal strategy notes:

• Cite FDA approvals explicitly (December 2024 OSA indication)
• For OSA: include sleep study results and CPAP trial documentation
• For obesity: emphasize BMI history, comorbidities, and prior intervention
• Request peer-to-peer review before formal appeal
• Track all deadlines

Decision framework

If you have UnitedHealthcare commercial coverage and BMI 30+: Submit standard PA with comorbidity documentation. Expect approval if criteria met.

If you have established moderate-to-severe OSA: Pursue the OSA indication separately. This pathway often succeeds where obesity-only requests fail.

If you have type 2 diabetes: Discuss Mounjaro with your physician. Same molecule, more accessible coverage.

If your employer plan excludes anti-obesity drugs: Explore the OSA pathway if applicable. Consider LillyDirect for out-of-pocket option.

If you have UnitedHealthcare Medicare Advantage: Obesity-only requests face exclusion under Part D rules. OSA pathway provides coverage with appropriate documentation.

FAQ

Does OptumRx cover Zepbound? Plan-dependent. Many commercial plans cover with PA; self-funded plans can exclude.

What is OptumRx? Pharmacy benefit manager subsidiary of UnitedHealth Group, administering benefits for UnitedHealthcare and external payers.

What is the prior authorization for Zepbound at OptumRx? BMI 30+ or BMI 27+ with comorbidities, weight-management documentation, step therapy when applicable.

How much does Zepbound cost with OptumRx? Covered: $50 to $200. Uncovered: $1,000 retail or LillyDirect $349 to $499.

Does UnitedHealthcare use OptumRx? Yes; OptumRx is the in-house PBM.

Can I appeal an OptumRx Zepbound denial? Yes; multiple appeal pathways by plan type.

Does OptumRx cover Zepbound for sleep apnea? Coverage expanded since December 2024 with sleep-study documentation.

What if my employer excludes anti-obesity drugs? ERISA exclusions cannot be overridden. OSA pathway may apply for eligible members.

Sources

1. FDA, Zepbound (tirzepatide) prescribing information, OSA label expansion, December 2024
2. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea (SURMOUNT-OSA). New England Journal of Medicine. June 2024
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022
4. OptumRx Standard Formulary, 2026 plan year
5. UnitedHealthcare 2024 annual report, OptumRx and pharmacy benefit disclosures
6. Eli Lilly, LillyDirect Zepbound self-pay vial program materials, 2025-2026
7. Centers for Medicare and Medicaid Services, Part D weight-loss drug coverage guidance
8. Inflation Reduction Act of 2022, Part D out-of-pocket cap, effective 2025
9. Kaiser Family Foundation, Employer Health Benefits Survey, 2024
10. American Academy of Sleep Medicine, OSA Clinical Practice Guidelines, 2023 update
11. ERISA appeals procedures, US Department of Labor

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacy partners. We have no commercial relationship with OptumRx, UnitedHealth Group, UnitedHealthcare, or Eli Lilly. Coverage information reflects publicly available data as of May 2026 and is subject to change.

Compounded Medication Notice. Compounded tirzepatide prepared by 503A pharmacies is a different product from FDA-approved Zepbound or Mounjaro. Compounded preparations are not FDA-approved and not interchangeable with brand-name tirzepatide.

Results Disclaimer. Weight loss, AHI reduction, and metabolic outcomes from clinical trials reflect average effects in study populations. Individual responses vary by dose tolerability, adherence, and baseline metabolic status.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. OptumRx and UnitedHealthcare are registered marks of UnitedHealth Group Incorporated. Wegovy is a registered trademark of Novo Nordisk A/S. References are informational.